Inventor · disambiguated record
Gregory Hinkle
Also filed as: HINKLE GREGORY · HINKLE GREGORY J
96 granted patents·84 pending applications·719 citations·filing 2001–2025
99Inventor score
Files withALNYLAM PHARMACEUTICALS INC128ARROWHEAD PHARMACEUTICALS INC6ARROWHEAD RES CORP4FITZGERALD KEVIN4HINKLE GREGORY4
Top patents by PatentIndex Score
180 records- 0198US8168775B2Compositions and methods for inhibiting expression of transthyretinSAH DINAH WEN-YEE·Filed 2009·Granted May 1, 2012·84 cites·23 claims
- 0298US7314974B2Expression of microbial proteins in plants for production of plants with improved propertiesMONSANTO TECHNOLOGY LLC·Filed 2003·Granted Jan 1, 2008·191 cites·8 claims
- 0397US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
- 0497US11015201B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 25, 2021·6 cites·15 claims
- 0596US8273869B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2010·Granted Sep 25, 2012·17 cites·27 claims
- 0695US11834661B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·2 cites·65 claims
- 0795US11180757B117β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Nov 23, 2021·3 cites·30 claims
- 0895US10570393B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·17 cites·46 claims
- 0995US8741866B2Compositions and methods for inhibiting expression of transthyretinSAH DINAH WEN-YEE·Filed 2012·Granted Jun 3, 2014·29 cites·30 claims
- 1095US8598139B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2012·Granted Dec 3, 2013·15 cites·26 claims
- 1195US8546554B2Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A geneDE FOUGEROLLES ANTONIN·Filed 2009·Granted Oct 1, 2013·25 cites·23 claims
- 1294US11419942B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·2 cites·55 claims
- 1394US10934544B2Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·15 cites·23 claims
- 1494US10709728B2Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 14, 2020·6 cites·18 claims
- 1594US10238749B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 26, 2019·12 cites·44 claims
- 1694US9234196B2Compositions and methods for inhibiting expression of transthyretinALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Jan 12, 2016·18 cites·37 claims
- 1794US6833447B1Myxococcus xanthus genome sequences and uses thereofMONSANTO TECHNOLOGY LLC·Filed 2001·Granted Dec 21, 2004·113 cites·5 claims
- 1893US10400238B2Polynucleotide agents targeting complement component C5 and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 3, 2019·4 cites·22 claims
- 1993US10231988B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Mar 19, 2019·10 cites·28 claims
- 2093US9574192B2Serapina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 21, 2017·14 cites·36 claims
- 2192US10814007B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 27, 2020·3 cites·15 claims
- 2292US10597661B2Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 24, 2020·4 cites·24 claims
- 2391US11434487B2Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Sep 6, 2022·2 cites·31 claims
- 2491US11136582B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 5, 2021·4 cites·26 claims
- 2591US10767177B2Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Sep 8, 2020·4 cites·59 claims
- 2691US10240152B2Compositions and methods for inhibiting expression of transthyretinALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Mar 26, 2019·6 cites·53 claims
- 2790US11198872B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Dec 14, 2021·6 cites·33 claims
- 2890US10513703B2Hepatitis B virus (HBV) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Dec 24, 2019·6 cites·24 claims
- 2990US10030244B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 24, 2018·6 cites·28 claims
- 3090US8324368B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionGOLLOB JARED·Filed 2009·Granted Dec 4, 2012·12 cites·36 claims
- 3190US2024327834A1Lipid formulated compositions and methods for inhibiting expression of serum amyloid a geneALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3289US11408001B1Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·29 claims
- 3389US11142766B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 12, 2021·4 cites·21 claims
- 3489US11060091B2Hepatitis B virus (HBV) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·2 cites·45 claims
- 3589US10407679B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·5 cites·43 claims
- 3689US2025064943A1ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3788US10982215B2Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Apr 20, 2021·2 cites·20 claims
- 3888US8765932B2Compositions and methods for inhibiting expression of XBP-1 geneFITZGERALD KEVIN·Filed 2012·Granted Jul 1, 2014·4 cites·23 claims
- 3988US2025051765A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4087US12492401B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Dec 9, 2025·0 cites·23 claims
- 4187US10370666B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Aug 6, 2019·5 cites·18 claims
- 4287US2025207128A1Polynucleotide agents targeting complement component c5 and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4386US11866701B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jan 9, 2024·2 cites·24 claims
- 4486US10883107B2Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jan 5, 2021·2 cites·18 claims
- 4586US10287582B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted May 14, 2019·3 cites·18 claims
- 4686US2025257358A1KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4786US2025188475A1KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4885US10683504B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jun 16, 2020·2 cites·19 claims
- 4985US9540643B2Organic compositions to treat HSF1-related diseasesARROWHEAD RES CORP·Filed 2015·Granted Jan 10, 2017·3 cites·21 claims
- 5085US8481509B2Organic compositions to treat HSF1-related diseasesHINKLE GREGORY·Filed 2012·Granted Jul 9, 2013·6 cites·20 claims
Showing the top 50 of 180 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →